Literature DB >> 29020249

Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?

Richard R Watkins1,2, Stan Deresinski3.   

Abstract

Early administration of appropriate empiric antibiotics is essential for achieving the best possible outcomes in sepsis. Yet the choice of antibiotic therapy has become more challenging due to recent reports of nephrotoxicity with the combination of vancomycin and piperacillin/tazobactam, the "workhorse" regimen at many institutions. In this article we assess the evidence for nephrotoxicity and its possible mechanisms, provide recommendations for risk mitigation, address the advantages and disadvantages of alternative antibiotic choices, and suggest areas for future research.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Sepsis; nephrotoxicity; piperacillin/tazobactam; vancomycin

Mesh:

Substances:

Year:  2017        PMID: 29020249     DOI: 10.1093/cid/cix675

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.

Authors:  Naoto Okada; Masayuki Chuma; Momoyo Azuma; Shingen Nakamura; Hirokazu Miki; Hirofumi Hamano; Mitsuhiro Goda; Kenshi Takechi; Yoshito Zamami; Masahiro Abe; Keisuke Ishizawa
Journal:  Eur J Clin Pharmacol       Date:  2019-09-11       Impact factor: 2.953

2.  Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model.

Authors:  Miao He; Ernane Souza; Aleksas Matvekas; Ryan L Crass; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.

Authors:  Adam M Blevins; Jennifer N Lashinsky; Craig McCammon; Marin Kollef; Scott Micek; Paul Juang
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Evaluating the Safety of Trough Versus Area Under the Curve (AUC)-Based Dosing Method of Vancomycin With Concomitant Piperacillin-Tazobactam.

Authors:  Cassandra Karas; Kyle Manning; Darrell T Childress; Elizabeth W Covington; Melanie M Manis
Journal:  J Pharm Technol       Date:  2022-06-13

5.  Intravenous magnesium sulfate for prevention of vancomycin plus piperacillin-tazobactam induced acute kidney injury in critically ill patients: An open-label, placebo-controlled, randomized clinical trial.

Authors:  Hossein Khalili; Hamid Rahmani; Mostafa Mohammadi; Mohamadreza Salehi; Zahra Mostafavi
Journal:  Daru       Date:  2021-08-31       Impact factor: 4.088

6.  Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.

Authors:  Amy Legg; Niamh Meagher; Sandra A Johnson; Matthew A Roberts; Alan Cass; Marc H Scheetz; Jane Davies; Jason A Roberts; Joshua S Davis; Steven Y C Tong
Journal:  Clin Drug Investig       Date:  2022-10-10       Impact factor: 3.580

Review 7.  Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?

Authors:  Warren Rose; Michael Fantl; Matthew Geriak; Victor Nizet; George Sakoulas
Journal:  Clin Infect Dis       Date:  2021-12-16       Impact factor: 9.079

8.  Risk of Acute Kidney Injury in Combat-Injured Patients Associated With Concomitant Vancomycin and Extended-Spectrum β-Lactam Antibiotic Use.

Authors:  Joseph M Yabes; Laveta Stewart; Faraz Shaikh; Paul M Robben; Joseph L Petfield; Anuradha Ganesan; Wesley R Campbell; David R Tribble; Dana M Blyth
Journal:  J Intensive Care Med       Date:  2020-06-08       Impact factor: 2.889

9.  Eosinophilic pneumonia caused by cefepime: A case report and review.

Authors:  Bruce M Jones; E Yancey Murray; Courtney Crosby; Scott Rojas; Christopher M Bland
Journal:  IDCases       Date:  2021-05-19

10.  Vancomycin-Associated Tubular Casts and Vancomycin Nephrotoxicity.

Authors:  Ngoentra Tantranont; Yosu Luque; Mary Hsiao; Claire Haute; Lillian Gaber; Roberto Barrios; Horacio E Adrogue; Aïssata Niasse; Luan D Truong
Journal:  Kidney Int Rep       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.